NCT05289193
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma treatment 2 recruiting NCT05655312
MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma treatment 1 / 2 recruiting NCT05970497
A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors No drug interventions treatment 1 recruiting NCT06284590
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients treatment 2 active_not_recruiting NCT06551064
Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients treatment 1 recruiting NCT04013854
Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab treatment 2 recruiting NCT03200847
Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma treatment 1 / 2 active_not_recruiting NCT00003647
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma treatment 3 completed NCT04305145
Infliximab for Treatment of Immune Checkpoint Inhibitor Colitis treatment 2 recruiting NCT05732805
A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma treatment 3 recruiting NCT05940311
Versatile Ampification Single-Molecule Detection in Liquid Biopsy No drug interventions Not Available Not Available recruiting NCT06299878
MelPRO-0322 (CRISTINA Trial) [miCrobiome pRedIctS aPD1 effecTivnes In melaNoma pAtietns] No drug interventions Not Available Not Available recruiting NCT04007588
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma treatment 2 withdrawn NCT05370807
A Clinical Trial of Regorafenib in Patients With Pretreated Advanced Melanoma treatment 2 recruiting NCT04598009
Binimetinib and Imatinib for Unresectable Stage III-IV KIT-Mutant Melanoma treatment 2 recruiting NCT03161756
Evaluation of Denosumab in Combination With Immune Checkpoint Inhibitors in Patients With Unresectable or Metastatic Melanoma treatment 1 / 2 unknown_status NCT00030615
Decitabine in Treating Patients With Advanced Solid Tumors treatment 1 completed NCT06295159
Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma treatment 0 recruiting NCT05402059
Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice No drug interventions Not Available Not Available recruiting NCT00217542
Azacitidine and Recombinant Interferon Alfa-2b in Treating Patients With Stage III or Stage IV Melanoma or Stage IV Kidney Cancer That Cannot Be Removed By Surgery treatment 1 completed NCT04526899
Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma treatment 2 active_not_recruiting NCT02794636
Interferon Toxicities in Melanoma Treatment No drug interventions Not Available Not Available completed NCT06199713
Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients No drug interventions Not Available Not Available recruiting NCT03190824
Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma treatment 2 unknown_status NCT04154163
Appropriate Dosing to Optimise Personalised Cancer Treatments No drug interventions Not Available Not Available completed NCT03385486
Study of TBX-3400 in Patients With Stage III and IV Melanoma Resistant or Refractory to Immune Checkpoint Inhibitors treatment 1 recruiting NCT04207086
A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma treatment 2 active_not_recruiting NCT04079166
SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) treatment 2 recruiting NCT05171374
pRospective Evaluation of Clinical Outcomes in Patients With metAsTatIŃ melanOma Treated With dabrafeNib and trAmetinib in reaL practicE Not Available Not Available recruiting NCT03161431
SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab treatment 1 recruiting NCT00089362
Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors treatment 1 completed NCT02676869
Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma treatment 1 completed NCT00003646
Gene Therapy in Treating Patients With Stage III or Stage IV Melanoma treatment 2 completed NCT02073123
Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma treatment 1 / 2 completed NCT04455503
Study of Adjuvant Immunotherapy With EVX-02 and Anti-PD-1 treatment 1 / 2 terminated NCT00019890
Vaccine Therapy in Treating Patients With High-Risk Stage III or Completely Resected Metastatic Melanoma treatment 2 completed NCT05309421
A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma treatment 2 recruiting NCT04139902
Neoadjuvant PD-1 Inhibitor Dostarlimab (TSR-042) vs. Combination of Tim-3 Inhibitor Cobolimab (TSR-022) and PD-1 Inhibitor Dostarlimab (TSR-042) in Melanoma treatment 2 recruiting NCT05767879
(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma treatment 2 recruiting NCT01026051
Safety, Immune and Tumor Response to a Multi-component Immune Based Therapy (MKC1106-MT) for Patients With Melanoma No drug interventions treatment 2 terminated NCT01875653
Autologous Dendritic Cell-Tumor Cell Immunotherapy for Metastatic Melanoma treatment 3 terminated NCT04410445
Study to Compare Adjuvant Immunotherapy of Bempegaldesleukin Combined With Nivolumab Versus Nivolumab After Complete Resection of Melanoma in Patients at High Risk for Recurrence treatment 3 terminated NCT04741997
Adjuvant Therapy Based on Pathologic Response After Neoadjuvant Encorafenib Binimetinib in Melanoma treatment 0 recruiting NCT04513028
Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma No drug interventions treatment Not Available recruiting NCT05751928
A Study of Neoadjuvant Therapy With BCD-217 (Nurulimab + Prolgolimab) in Patients With Resectable Stage III Skin Melanoma treatment 3 recruiting NCT03605771
Descriptive Observational Study on the Characteristics of Advanced and Metastatic Melanoma in Spain No drug interventions Not Available Not Available recruiting NCT03153085
A Study of Combination With TBI-1401(HF10) and Ipilimumab in Japanese Patients With Unresectable or Metastatic Melanoma treatment 2 completed NCT05467137
Sentinel Lymph Node Detection in Patients With Stage Ib-III Melanoma Using MSOT and ICG No drug interventions diagnostic 4 unknown_status NCT05445752
Conservative Nodal Surgery (Node-picking) of Patients With Stage III Melanoma With Low-burden of Nodal Disease (MELCONSURG MULTICENTRE COHORT) No drug interventions Not Available Not Available recruiting NCT00082875
Cilengitide in Treating Patients With Unresectable or Metastatic Melanoma treatment 2 terminated NCT06508775
Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies other Not Available recruiting NCT05827770
The Efficacy and Safety of Neoadjuvant Toripalimab Combined With Temozolomide in Resectable Stage III Melanoma treatment 2 not_yet_recruiting NCT00349206
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 1 completed NCT00119249
Sorafenib in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed By Surgery treatment 2 completed NCT05079113
Leveraging ctDNA Analysis to Improve Early Detection of Cancer Recurrence in the High-Risk Melanoma Setting No drug interventions Not Available Not Available completed NCT01376713
Anti-CD20 (Cluster of Differentiation Antigen 20) Therapy to Treat Metastatic Melanoma treatment 2 completed NCT03620019
Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma treatment 2 completed NCT04059224
TraMel-WT: A Trial of Trametinib in Patients With Advanced Pretreated BRAFV600 Wild-type Melanoma treatment 2 completed NCT00087386
Tanespimycin in Treating Patients With Stage III-IV Melanoma treatment 2 terminated NCT04330430
Neo-adjuvant T-VEC + Nivolumab Combination Therapy for Resectable Early Metastatic (Stage IIIB/C/D-IV M1a) Melanoma With Injectable Disease treatment 2 active_not_recruiting NCT04703426
Sargramostim (GM-CSF) + PD-1 treatment 2 withdrawn NCT01107665
Pazopanib and Paclitaxel as First-Line Treatment for Subjects With Unresectable Stage III and Stage IV Melanoma treatment 2 completed NCT03719131
Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy treatment 2 active_not_recruiting NCT05652673
Safe Stop Ipilimumab-nivolumab (IPI-NIVO) Trial treatment Not Available recruiting NCT04045691
Binimetinib Plus Encorafenib Real Life Investigation of Next Generation Melanoma Treatment Not Available Not Available recruiting NCT06204991
To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma treatment 1 not_yet_recruiting NCT04562129
IL2 With Ipilimumab Followed by Nivolumab in Stage 3 or 4 Melanoma Patients treatment 2 recruiting NCT05251389
FMT to Convert Response to Immunotherapy No drug interventions treatment 1 / 2 recruiting NCT00003789
Melphalan With or Without Tumor Necrosis Factor in Treating Patients With Locally Advanced Melanoma of the Arm or Leg treatment 3 completed NCT00945269
Therapeutic Autologous Lymphocytes, Aldesleukin, and Denileukin Diftitox in Treating Patients With Stage III-IV Melanoma treatment 1 / 2 terminated NCT04675346
Exploring Unmet Needs and Attitudes to Skin Self-examination in Melanoma Survivors No drug interventions Not Available Not Available completed NCT00450255
VEGF Trap in Treating Patients With Recurrent Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery treatment 2 completed NCT02306850
Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma treatment 2 completed NCT01168050
Efficacy of Nilotinib in First or Second Line Treatment of Primary Melanomas Stage III Unresectable Melanomas. treatment 2 unknown_status NCT00074308
Imatinib Mesylate and Bevacizumab in Treating Patients With Advanced Melanoma or Other Advanced Cancers treatment 1 / 2 completed NCT01851408
Sorafenib and Temsirolimus in Treating Patients With Metastatic, Recurrent, or Unresectable Melanoma treatment 2 withdrawn NCT01726738
LCCC 1128: Open Label Phase II Trial of the BRAF Inhibitor (Dabrafenib) and the MEK Inhibitor (Trametinib) in Unresectable Stage III and Stage IV BRAF Mutant Melanoma; Correlation of Resistance With the Kinome and Functional Mutations treatment 2 completed